Features of comorbidities diseases and comorbidity in patients with acute myeloid leukemia younger than 60 years

Abstract

The frequency and structure of associated diseases in patients with acute myeloid leukaemia younger than 60 years were analyzed. It has been established that the most frequent associated diseases in this age group of patients are diseases of the respiratory, digestive and cardiovascular systems. In most patients with acute myeloid leukaemia younger than 60 years, was diagnosed one concomitant disease with a tendency to increase their number with increasing age. Application for assessing the level of comorbidity in patients with acute myeloid leukemia younger than 60 years comorbidity index in the transplantation of hematopoietic cells, of scale assessment of adult comorbidity and the level of cumulative disease assessment in the elderly, the Cumulative Illness Rating Scale for Geriatrics makes it possible to evenly divide them into subgroups, depending on the degree of comorbidity, with the identification of statistically significant differences in the 5-year overall survival. According to the results of χ2 and log-rank p, the most optimal scale for assessing comorbidity in patients with acute myeloid leukaemia younger than 60 years occur Hematopoietic Cell Transplant Specific Comorbidity Index. With increasing age patients with acute myeloid leukaemia younger than 60 years, there is an increase in the number of patients with intermediate and high levels of comorbidity, while the number of patients with low levels of comorbidity decreases. The results show that it is advisable to use the degree of comorbidity in patients with acute myeloid leukemia younger than 60 years as a prognostic factor in the possibility of achieving a 5-years overall survival.

Keywords

acute myeloid leukemia / hematopoietic cell transplantation / allogeneic bone marrow transplantation / comorbidities diseases / comorbidity / 5-years overall survival

References

[1] Горяинова, Н.В. Значение коморбидности для стратификации лечения острых миелоидных лейкозов у взрослых / Н.В. Горяинова // Медичні науки Scientific Journal «ScienceRise». – 2015. – № 6–4 (11). – С. 68–72.

[2] Рукавицын, О.А. Гематология: национальное руководство / О.А. Рукавицын. – М.: ГЭОТАР-Медиа, 2015. – 776 с.

[3] Arber, D.A. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia / D.A. Arber [et al.] // Blood. – 2016. – Vol. 127, № 20. – Р. 2391–2405.

[4] Bennett, J.M. Proposals for the classification of the acute leukaemias: French – American – British Cooperative Group / J.M. Bennett [et al.] // Br. J. Haematol. – 1976. – Vol. 33 – P. 451–458.

[5] Charlson, M.E. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation / M.E. Charlson [et al.] // J. Chronic Dis. – 1987. – Vol. 40, № 5. – Р. 373–383.

[6] Colella, M.P. Hematopoietic Cell Transplant Specific Comorbidity Index, Disease Status at Transplant and Graft Source as Risk Factors in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant / M.P. Colella [et al.] // J. Hematol Transfus. – 2014. – Vol. 2, № 3. – Р. 1031.

[7] Damm, F. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype / F. Damm [et al.] // Blood. – 2011. – Vol. 117, № 17. – Р. 4561–4568.

[8] Greenfield, S. The importance of coexistent disease in the occurrence of postoperative complications and one–year recovery in patients undergoing total hip replacement: Comorbidity and outcomes after hip replacement / S. Greenfield [et al.] // Med. Care. 1993. – Vol. 31, № 2. – P. 141–154.

[9] Imamura, K. Reliability of a comorbidity measure: the Index of co–existent disease (ICED) / K. Imamura [et al.] // J. Clin. Epidemiol. – 1997. – Vol. 50, № 9. – P. 1011–1016.

[10] Liersch, R. Prognostic factors for acute myeloid leukaemia in adults–biological significance and clinical use / R. Liersch [et al.] // Br. J. Haematol. – 2014. – Vol. 165, № 1. – Р. 17–38.

[11] Kaplan, M.H. Acritique of methods in reported studies of long– term vascular complications in patients with diabetes mellitus / M.H. Kaplan, A.R. Feinstein // Diabetes. – 1973. – Vol. 22, № 3. – Р. 160–174.

[12] Mohammadi, M. The impact of comorbid disease history on all–cause and cancer–specific mortality in myeloid leukemia and myeloma – a Swedish population–based study / M. Mohammadi [et al.] // BMC Cancer. – 2015. – Vol. 5, № 15. – Р. 850.

[13] Piccirillo, J.F. Prognostic importance of comorbidity in a hospital–based cancer registry / J.F. Piccirillo [et al.] // JAMA. – 2004. – Vol. 291, № 20. – Р. 2441–2447.

[14] Roellig, С. Long - term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendation: evolution of the proposed reporting system / C. Roellig [et al.] //J. of Clin. Oncology. – 2011. – Vol. 29, № 20. – P. 2758–2765.

[15] Salvi, F. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients / F. Salvi. [et al.] // J. Am. Geriatr. Soc. – 2008. – Vol. 56, № 10. – Р. 1926–1931.

[16] Sorror, M.L. Hematopoietic cell transplantation (HCT) – specific comorbidity index: a new tool for risk assessment before allogeneic HCT / M.L. Sorror [et al.] // Blood. – 2005. – Vol. 106, № 8. – P. 2912–2919.

[17] Vardiman, J.W. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes / J.W. Vardiman [et al.] // Blood. – 2009. – Vol. 114, № 5. – P. 937–951.

[18] Wass, M. Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia / M. Wass [et al.] // PLoS One. – 2016. – Vol. 11, № 10. – P. 1–13.

[19] Yancik, R. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base / R. Yancik [et al.] // J. Clin. Oncol. – 2001. – № 19. – Р. 1147–1151.

RIGHTS & PERMISSIONS

Semelev V.N., Tyrenko V.V., Yurkin A.K., Bondarchuk S.V., Gornostaev D.A., Bogdanov A.N., Voloshin S.V., Uspenskaya O.S., Karyagina E.V.